mTORC2-Akt1级联对c-Myc促进小鼠和人类肝细胞癌发生至关重要
研究探讨mTORC2/Akt1在c-Myc驱动肝细胞癌中的作用。小鼠实验显示Rictor或Akt1缺失可完全阻止c-Myc诱导的肝癌形成,而Akt2缺失无此作用;人肝癌样本中c-MYC激活与磷酸化AKT1强相关,RICTOR和AKT1高表达与患者生存差相关。在c-Myc小鼠中,mTORC1抑制剂雷帕霉素效果有限,而mTORC1/mTORC2双重抑制剂MLN0128有效促进肿瘤消退。
要点
- mTORC2在c-Myc驱动的小鼠肝癌中激活,导致Akt1而非Akt2磷酸化/活化。
- Akt1缺失完全阻止c-Myc肝癌形成,而Akt2缺失无此作用。
- 人肝癌中c-MYC激活与磷酸化AKT1强相关,RICTOR和AKT1高表达与生存差相关。
核心结论
- mTORC2/Akt1沿c-Myc诱导的肝细胞癌发生发挥功能性作用,AKT1和AKT2在肝癌发生和进展中角色不同。
- 靶向mTORC1和mTORC2两者可能对治疗显示c-Myc扩增或过表达的人肝癌是必要的。
研究设计与样本
- 研究采用c-Myc驱动的小鼠肝细胞癌模型、肝癌细胞系体外实验及人肝癌样本分析。
主要发现
- 在c-Myc驱动的小鼠肝癌中mTORC2被激活,导致Akt1而非Akt2磷酸化/活化。
- Rictor缺失抑制体内c-Myc诱导的肝癌形成。
- Akt1缺失完全阻止小鼠c-Myc肝癌形成,而Akt2缺失无此作用。
- 在c-Myc肝癌细胞系中沉默Rictor或Akt1抑制磷酸化叉头框o1表达并强烈抑制体外细胞生长。
- 人肝癌样本中c-MYC激活与磷酸化AKT1表达强相关,RICTOR和AKT1(而非AKT2)高表达与患者生存差相关。
临床怎么用
- 作者认为靶向mTORC1和mTORC2两者可能对治疗显示c-Myc扩增或过表达的人肝癌是必要的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinoma (HCC) is a deadly form of liver cancer with limited treatment options. The c-Myc transcription factor is a pivotal player in hepatocarcinogenesis, but the mechanisms underlying c-Myc oncogenic activity in the liver remain poorly delineated. Mammalian target of rapamycin complex 2 (mTORC2) has been implicated in cancer by regulating multiple AGC kinases, especially AKT proteins. In the liver, AKT1 and AKT2 are widely expressed. While AKT2 is the major isoform downstream of activated phosphoinositide 3-kinase and loss of phosphatase and tensin homolog-induced HCC, the precise function of AKT1 in hepatocarcinogenesis is largely unknown. In the present study, we demonstrate that mTORC2 is activated in c-Myc-driven mouse HCC, leading to phosphorylation/activation of Akt1 but not Akt2. Ablation of Rictor inhibited c-Myc-induced HCC formation in vivo. Mechanistically, we discovered that loss of Akt1, but not Akt2, completely prevented c-Myc HCC formation in mice. Silencing of Rictor or Akt1 in c-Myc HCC cell lines inhibited phosphorylated forkhead box o1 expression and strongly suppressed cell growth in vitro. In human HCC samples, c-MYC activation is strongly correlated with phosphorylated AKT1 expression. Higher expression of RICTOR and AKT1, but not AKT2, is associated with poor survival of patients with HCC. In c-Myc mice, while rapamycin, an mTORC1 inhibitor, had limited efficacy at preventing c-Myc-driven HCC progression, the dual mTORC1 and mTORC2 inhibitor MLN0128 effectively promoted tumor regression by inducing apoptosis and necrosis. Conclusion: Our study indicates the functional contribution of mTORC2/Akt1 along c-Myc-induced hepatocarcinogenesis, with AKT1 and AKT2 having distinct roles in HCC development and progression; targeting both mTORC1 and mTORC2 may be required for effective treatment of human HCC displaying c-Myc amplification or overexpression.
引用
- Xu Z, Xu M, Liu P, et al. The mTORC2-Akt1 Cascade Is Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans. Hepatology. 2019. PMID: 31062368. doi:10.1002/hep.30697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。